BEACON has been set up to facilitate continuation as a multi-arm multi-stage platform trial to permit the inclusion of additional treatment arms in the future. To our knowledge, this represents the first platform trial for inflammatory skin disease. An aligned bioresource for biomarker discovery will run in parallel to inform future personalised therapy. The first planned additional arm for BEACON is a JAK inhibitor (abrocitinib), in collaboration with Pfizer.
We would be delighted to speak to industrial partners regarding any aspect of our programme and the potential inclusion of novel therapeutics into the platform.
If you are interested in discussing this, please contact catherine.smith@kcl.ac.uk, copying in BEACON@kcl.ac.uk.
